Related Experiment Videos
The epidemiologic approach to pharmacogenomics.
Julian Little1, Linda Sharp, Muin J Khoury
1Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Rd, Ottawa, Ontario K1H 8M5, Canada. jlittle@uottawa.ca
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|February 25, 2005
Summary
Epidemiologic methods systematically evaluate genomic information for safer, more effective drug treatments. Various study designs are needed, with data pooling essential for robust gene-drug interaction research.
Area of Science:
- Epidemiology
- Pharmacogenomics
- Genomic Medicine
Background:
- Genomic information offers potential for optimizing drug safety and efficacy.
- Targeted drug treatments based on genetic profiles are an emerging area in medicine.
Purpose of the Study:
- To systematically evaluate epidemiologic approaches for assessing gene-drug interactions.
- To explore the utility of various study designs in pharmacogenomic research.
Main Methods:
- Review of established epidemiologic designs: randomized control trials, cohort studies, and case-control studies.
- Discussion of designs for gene-environment interactions and methodological challenges like bias and confounding.
- Consideration of data pooling and novel designs for gene-drug interaction studies.
Main Results:
- No single epidemiologic design is universally optimal for gene-drug interaction studies.
- Methodological issues such as bias, confounding, and chance must be addressed.
- A portfolio of evidence from diverse designs is necessary to establish gene-drug interactions.
Conclusions:
- Exploiting existing trial samples and utilizing population-based registries can facilitate gene-treatment interaction research.
- Case-only designs within randomized controlled trials may reduce genotyping costs.
- Pooling data across studies is crucial for achieving adequate statistical power to test hypotheses on complex gene-drug interactions.